Page de couverture de 1. ctDNA Tumor Fraction Matters When Interpreting Liquid Biopsy Test Results

1. ctDNA Tumor Fraction Matters When Interpreting Liquid Biopsy Test Results

1. ctDNA Tumor Fraction Matters When Interpreting Liquid Biopsy Test Results

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

 Today we are talking with Dr. Lincoln Pasquina, Director of Clinical Development at Foundation Medicine. Dr. Pasquina leads a team that is on the cutting edge of the newest advances in comprehensive genomic profiling. These genomic tests help providers with therapy selection for their patients, expand the number of people who can enroll in trials, increase access to therapies for patients, and accelerate new drug development. Right now, his focus is on liquid biopsy and Foundation Medicine's new ctDNA tumor fraction algorithm that improves confidence in the test, especially when supporting next step decision making concerning negative results.

Ce que les auditeurs disent de 1. ctDNA Tumor Fraction Matters When Interpreting Liquid Biopsy Test Results

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.